Avadel Pharmaceuticals Plc (AVDL)
21.64
0.00 (0.00%)
USD |
NASDAQ |
Sep 04, 16:00
Avadel Pharmaceuticals Research and Development Expense (Quarterly) : 27.01M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2025 | 27.01M |
| June 30, 2025 | 4.255M |
| March 31, 2025 | 4.354M |
| December 31, 2024 | 4.274M |
| September 30, 2024 | 3.803M |
| June 30, 2024 | 4.051M |
| March 31, 2024 | 3.068M |
| December 31, 2023 | 2.359M |
| September 30, 2023 | 2.849M |
| June 30, 2023 | 4.223M |
| March 31, 2023 | 3.83M |
| December 31, 2022 | 6.235M |
| September 30, 2022 | 2.933M |
| June 30, 2022 | 4.541M |
| March 31, 2022 | 6.991M |
| December 31, 2021 | 2.11M |
| September 30, 2021 | 4.38M |
| June 30, 2021 | 6.762M |
| March 31, 2021 | 3.852M |
| December 31, 2020 | 5.286M |
| September 30, 2020 | 5.569M |
| June 30, 2020 | 4.057M |
| March 31, 2020 | 5.53M |
| December 31, 2019 | 7.757M |
| September 30, 2019 | 7.539M |
| Date | Value |
|---|---|
| June 30, 2019 | 10.29M |
| March 31, 2019 | 7.329M |
| December 31, 2018 | 6.086M |
| September 30, 2018 | 11.40M |
| June 30, 2018 | 11.89M |
| March 31, 2018 | 9.951M |
| December 31, 2017 | 12.12M |
| September 30, 2017 | 8.095M |
| June 30, 2017 | 6.792M |
| March 31, 2017 | 7.206M |
| December 31, 2016 | 13.48M |
| September 30, 2016 | 8.143M |
| June 30, 2016 | 7.604M |
| March 31, 2016 | 5.388M |
| December 31, 2015 | 5.161M |
| September 30, 2015 | 7.221M |
| June 30, 2015 | 7.204M |
| March 31, 2015 | 6.022M |
| December 31, 2014 | 5.636M |
| September 30, 2014 | 7.028M |
| June 30, 2014 | 6.742M |
| March 31, 2014 | 3.944M |
| December 31, 2013 | 1.951M |
| September 30, 2013 | 6.68M |
| June 30, 2013 | 7.304M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Jazz Pharmaceuticals Plc | 207.50M |
| Perrigo Co. Plc | 23.70M |
| GH Research Plc | 12.40M |
| Cosmo NV | -- |
| Alkermes Plc | 111.12M |